242 related articles for article (PubMed ID: 34735919)
21. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
26. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.
Yun T; Qin T; Liu Y; Lai L
ChemMedChem; 2016 Apr; 11(7):713-7. PubMed ID: 27061239
[TBL] [Abstract][Full Text] [Related]
28. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
[TBL] [Abstract][Full Text] [Related]
29. Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models.
Gunasekaran P; Yim MS; Ahn M; Soung NK; Park JE; Kim J; Bang G; Shin SC; Choi J; Kim M; Kim HN; Lee YH; Chung YH; Lee K; EunKyeong Kim E; Jeon YH; Kim MJ; Lee KR; Kim BY; Lee KS; Ryu EK; Bang JK
J Med Chem; 2020 Dec; 63(23):14905-14920. PubMed ID: 33142063
[TBL] [Abstract][Full Text] [Related]
30. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
Zhao XZ; Tsuji K; Hymel D; Burke TR
Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
[TBL] [Abstract][Full Text] [Related]
31. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
[TBL] [Abstract][Full Text] [Related]
32. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
33. Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
Narvaez AJ; Ber S; Crooks A; Emery A; Hardwick B; Guarino Almeida E; Huggins DJ; Perera D; Roberts-Thomson M; Azzarelli R; Hood FE; Prior IA; Walker DW; Boyce R; Boyle RG; Barker SP; Torrance CJ; McKenzie GJ; Venkitaraman AR
Cell Chem Biol; 2017 Aug; 24(8):1017-1028.e7. PubMed ID: 28807782
[TBL] [Abstract][Full Text] [Related]
34. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
35. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
38. [Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer].
Fu Z; Su M; Liu X; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2298-2312. PubMed ID: 33244925
[TBL] [Abstract][Full Text] [Related]
39. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T
J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981
[TBL] [Abstract][Full Text] [Related]
40. Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.
Scharow A; Raab M; Saxena K; Sreeramulu S; Kudlinzki D; Gande S; Dötsch C; Kurunci-Csacsko E; Klaeger S; Kuster B; Schwalbe H; Strebhardt K; Berg T
ACS Chem Biol; 2015 Nov; 10(11):2570-9. PubMed ID: 26279064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
